Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Update

Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 6,000 shares, a growth of 42.9% from the March 15th total of 4,200 shares. Based on an average daily volume of 4,900 shares, the short-interest ratio is currently 1.2 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. increased its position in Adlai Nortye Ltd. (NASDAQ:ANL - Free Report) by 128.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,310 shares of the company's stock after purchasing an additional 22,644 shares during the quarter. Cantor Fitzgerald L. P. owned approximately 0.11% of Adlai Nortye worth $362,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 35.21% of the company's stock.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an "overweight" rating on shares of Adlai Nortye in a research note on Friday, January 12th.

Adlai Nortye Trading Down 4.4 %

Shares of NASDAQ ANL traded down $0.49 during trading on Friday, reaching $10.56. The company had a trading volume of 3,726 shares, compared to its average volume of 6,263. Adlai Nortye has a 52 week low of $7.11 and a 52 week high of $19.30. The business's 50 day moving average is $8.60.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.